El Gen c-MYC en caninos: Un regulador clave en la patogénesis tumoral y posible blanco terapéutico:  c-MYC gene in canines: A key regulator in tumor pathogenesis and a potential therapeutic target

Arnulfo Villanueva Castillo; Ruby Sandy Moreno Mejía; Carlos Gerardo Castillo Sosa; Cesar Feliciano Pastelín Rojas; Hermilo Lucio Castillo; Fatima Matamoros González; Alexis Cruz Espinosa; Arturo Órnelas Luna

doi:10.19137/cienvet.v27.9045

Authors

Arnulfo Villanueva Castillo Facultad de Medicina Veterinaria y Zootecnia de la Benemérita Universidad Autónoma de Puebla (BUAP) https://orcid.org/0000-0002-9430-1503
Ruby Sandy Moreno Mejía Facultad de Medicina Veterinaria y Zootecnia de la Benemérita Universidad Autónoma de Puebla
Carlos Gerardo Castillo Sosa Facultad de Medicina Veterinaria y Zootecnia de la Benemérita Universidad Autónoma de Puebla
Cesar Feliciano Pastelín Rojas Facultad de Medicina Veterinaria y Zootecnia de la Benemérita Universidad Autónoma de Puebla
Hermilo Lucio Castillo Unidad Académica Multidisciplinaria Mante de la Universidad Autónoma de Tamaulipas https://orcid.org/0000-0001-7917-3075
Fatima Matamoros González Facultad de Medicina Veterinaria y Zootecnia de la Benemérita Universidad Autónoma de Puebla
Alexis Cruz Espinosa Facultad de Medicina Veterinaria y Zootecnia de la Benemérita Universidad Autónoma de Puebla
Arturo Órnelas Luna Facultad de Medicina Veterinaria y Zootecnia de la Benemérita Universidad Autónoma de Puebla

DOI:

https://doi.org/10.19137/cienvet.v27.9045

Keywords:

c-MYC, Oncogene, Canine neoplasms, Targeted therapy, Comparative oncology

Abstract

The c-MYC oncogene is emerging as a key regulator in the pathogenesis of canine tumors and is established as a priority therapeutic target. This gene is vital for cellular homeostasis, being
involved in processes such as proliferation, differentiation, metabolism, and apoptosis. Its
deregulation, frequently due to gene amplification or chromosomal rearrangements, has been
associated with various canine neoplasias: transmissible venereal tumor TVT, mammary tumors, osteosarcomas, and prostate and ocular carcinomas. In the case of TVT, the insertion of LINE-1 elements in c-MYC highlights it as a relevant diagnostic marker. Abnormal c-MYC expression is associated with aggressiveness and rapid tumor progression, consolidating its potential as a diagnostic marker and therapeutic target. Although direct c-MYC inhibition presents technical challenges, current strategies seek to modulate its activity by inhibiting upstream signaling pathways or modifying its protein interactions. These advances could significantly improve the treatment of canine neoplasia. In comparative oncology, canine models are valuable for studying human tumor biology due to pathological similarities and spontaneous tumors. Analysis of c-MYC offers a platform for investigating shared oncogenic mechanisms and evaluating therapeutic interventions before their application in human medicine. Thus, the study of c-MYC is crucial in cancer research in both veterinary and human medicine

Author Biographies

Arnulfo Villanueva Castillo, Facultad de Medicina Veterinaria y Zootecnia de la Benemérita Universidad Autónoma de Puebla (BUAP)

Académico e investigador especializado en enfermedades veterinarias, con sólida trayectoria en bioinformática, patología molecular y salud animal. Actualmente, adscripto a la Benemérita Universidad Autónoma de Puebla (BUAP), donde lidera el cuerpo académico BUAP-CA-274 “Enfermedades Emergentes, Bioinformática y Dinámica Molecular”. Su línea de investigación se centra en los mecanismos de adaptación de agentes etiológicos y hospederos en enfermedades infecciosas zoonóticas, así como en enfermedades transmisibles emergentes. Posee el perfil PRODEP y está registrado en el Sistema Nacional de Investigadores (SNI) con nivel C, vigente hasta 2027. Jefe del Laboratorio De Biología Molecular Y Biotecnología Veterinaria. Ha publicado estudios sobre paratuberculosis bovina, actividad ovárica posparto en vacas de carne, celo en cabras sincronizadas, y diagnóstico histopatológico de neoplasias mamarias en perras. Participa en investigaciones sobre resistencia a enfermedades priónicas en ovinos, bioinformática del gen mecC en Staphylococcus aureus, y enterobacterias productoras de ß-lactamasas en felinos domésticos.
Ruby Sandy Moreno Mejía, Facultad de Medicina Veterinaria y Zootecnia de la Benemérita Universidad Autónoma de Puebla

Contribución Principal: Recolección y procesamiento de muestras biológicas, análisis histopatológico de tumores caninos y recolección de datos clínicos. Rol Específico: Responsable de la caracterización histológica de los casos estudiados, incluyendo la evaluación de figuras mitóticas y cariomegalia. Responsabilidad: Asegurar la precisión de los datos histológicos y su integración en el análisis final.
Carlos Gerardo Castillo Sosa , Facultad de Medicina Veterinaria y Zootecnia de la Benemérita Universidad Autónoma de Puebla

Académico. Área de Microbiología Veterinaria.
Cesar Feliciano Pastelín Rojas , Facultad de Medicina Veterinaria y Zootecnia de la Benemérita Universidad Autónoma de Puebla

Académico. Área de Fisio-neurología
Hermilo Lucio Castillo, Unidad Académica Multidisciplinaria Mante de la Universidad Autónoma de Tamaulipas

Académico. Área de Biología Molecular y Parasitología Veterinaria.
Fatima Matamoros González , Facultad de Medicina Veterinaria y Zootecnia de la Benemérita Universidad Autónoma de Puebla

Estudiante de posgrado. Maestría en producción animal sustentable.
Alexis Cruz Espinosa , Facultad de Medicina Veterinaria y Zootecnia de la Benemérita Universidad Autónoma de Puebla

Estudiante. Licenciatura Medicina Veterinaria y Zootecnia.
Arturo Órnelas Luna , Facultad de Medicina Veterinaria y Zootecnia de la Benemérita Universidad Autónoma de Puebla

Estudiante. Licenciatura en Medicina Veterinaria y Zootecnia.

References

Dang CV, et al. Function of the c-Myc oncogenic transcription factor. Experimental Cell Research, 1999; 253(1), 63–77. Disponible en: https://doi.org/10.1006/excr.1999.46

Miyamoto MM, Porter CA, Goodman M. c-myc gene sequences and the phylogeny of bats and other eutherian mammals. Systematic Biology,2000; 49(3). Disponible en: https://doi.org/10.1080/10635159950127367

Mortlock SA, et al. Genomic Analysis of Lymphoma Risk in Bullmastiff Dogs. Veterinary Sciences, 2023;10(12). Disponible en: https://doi.org/10.3390/vetsci10120703

Manzoor S et al. C-Myc has altered expression in canine and feline tumors. Pakistan Journal of Zoology, 2017; 49(6) Disponible en: https://doi.org/10.17582/journal.pjz/2017.49.6.2147.2152

Harmelin A et al. Use of a murine xenograft model for canine transmissible venereal tumor. American Journal of Veterinary Research, 2001; 62(6). Disponible en: https://doi.org/10.2460/ajvr.2001.62.907

Katzir N et al. “Retroposon” insertion into the cellular oncogene c-myc in canine transmissible venereal tumor. Proceedings of the National Academy of Sciences of the United States of America, 1985; 82(4), 1054–1058. Disponible en: https://doi.org/10.1073/pnas.82.4.1054

Liao K.-W et al. Identification of canine transmissible venereal tumor cells using in situ polymerase chain reaction and the stable sequence of the long interspersed nuclear element. In J Vet Diagn Invest, 2003a (Vol. 15).

Ojeda J, Alfaro A, Moroni M, Camacho V, Martínez J & Noro M. Tumor venéreo transmisible diseminado sobre piel, párpados y pene en un perro. Reporte de caso. Archivos de Medicina Veterinaria,2016; 48(1). Disponible en: https://doi.org/10.4067/S0301-732X2016000100015

Borge KS. Canine mammary tumours are affected by frequent copy number aberrations, Including amplification of myc and loss of pten. PLoS ONE, 2015;10(5). Disponible en: https://doi.org/10.1371/journal.pone.0126371

Gola C. The mitotic regulator polo-like kinase 1 as a potential therapeutic target for c-Myc-overexpressing canine osteosarcomas. Veterinary and Comparative Oncology, 2022; 20(4). Disponible en: https://doi.org/10.1111/vco.12854

Fonseca-Alves CE, Kobayashi PE, Laufer-Amorim R. Evaluation of NKX3.1 and C-MYC expression in canine prostatic cancer. Research in Veterinary Science, 2018; 118.Disponible en: https://doi.org/10.1016/j.rvsc.2018.04.001

Lopes RA, Cardoso TC, Luvizotto MCR, de Andrade AL. Occurrence and expression of p53 suppressor gene and c-Myc oncogene in dog eyelid tumors. Veterinary Ophthalmology, 2010; 13(2), 69–75. Disponible en: https://doi.org/10.1111/j.1463-5224.2009.00753.x

Ahmad W et al. Assessment of tumor-induced pain and C-reactive protein levels in dogs with canine transmissible venereal tumors. Turkish Journal of Veterinary and Animal Sciences, 2018; 42(5), 429–434. Disponible en: https://doi.org/10.3906/vet-1805-54

Frazier KS, Hines ME, Hurvitz AI, Robinson PG, Herron AJ. Analysis of DNA Aneuploidy and c-myc Oncoprotein Content of Canine Plasma Cell Tumors Using Flow Cytometry. Veterinary Pathology, 1993; 30(6), 505–511. Disponible en: https://doi.org/10.1177/030098589303000603

Katavolos P et al. Preclinical Safety Assessment of a Highly Selective and Potent Dual Small-Molecule Inhibitor of CBP/P300 in Rats and Dogs. Toxicologic Pathology, 2020; 48(3). Disponible en:https://doi.org/10.1177/0192623319898469

Sibuh BZ, Khanna S, Taneja P, Sarkar P, Taneja NK. Molecular docking, synthesis and anticancer activity of thiosemicarbazone derivatives against MCF-7 human breast cancer cell line. Life Sciences, 2021; 273. Disponible en: https://doi.org/10.1016/j.lfs.2021.119305

Beffagna G et al. Circulating cell-free DNA in dogs with mammary tumors: Short and long fragments and integrity index. PLoS ONE,2017; 12(1). Disponible en: https://doi.org/10.1371/journal.pone.0169454

Lima CR et al. Insertion of the LINE-1 element in the C-MYC gene and immunoreactivity of C-MYC, p53, p21 and p27 proteins in different morphological patterns of the canine TVT. Arquivo Brasileiro de Medicina Veterinaria e Zootecnia, 2016; 68(3).Disponible en: https://doi.org/10.1590/1678-4162-8750

Reuse S, Maenhaut C, Dumont JE. Regulation of protooncogenes c-fos and c-myc expressions by protein tyrosine kinase, protein kinase C, and cyclic AMP mitogenic pathways in dog primary thyrocytes: A positive and negative control by cyclic AMP on c-myc expression. Experimental Cell Research,1990; 189(1). Disponible en: https://doi.org/10.1016/0014-4827(90)90253-7

Liao K.-W et al. Identification of canine transmissible venereal tumor cells using in situ polymerase chain reaction and the stable sequence of the long interspersed nuclear element. In J Vet Diagn Invest (2003b) (Vol. 15).

Marei HE et al. p53 signaling in cancer progression and therapy. In Cancer Cell International (Vol. 21, Issue 1). BioMed Central Ltd.2021; Disponible en: https://doi.org/10.1186/s12935-021-02396-8

Mrdenovic S et al, Targeting Burkitt lymphoma with a tumor cell–specific heptamethine carbocyanine-cisplatin conjugate. Cancer, 2019; 125(13). Disponible en: https://doi.org/10.1002/cncr.32033

Inoue M, & Shiramizu K. Immunohistochemical detection of p53 and c-myc proteins in canine mammary tumours. Journal of Comparative Pathology, 1999; 120(2). Disponible en: https://doi.org/10.1053/jcpa.1998.0268

Ni T et al. PTBP1 drives c-Myc-dependent gastric cancer progression and stemness. British Journal of Cancer, 2023; 128(6), 1005–1018. Disponible en: https://doi.org/10.1038/s41416-022-02118

Beebe E el al. Proteomic profiling of canine fibrosarcoma and adjacent peritumoral tissue. Neoplasia (United States), 2023; 35. Disponible en: https://doi.org/10.1016/j.neo.2022.100858

Kobayashi M et al. Canine intestinal mast cell tumor with c-kit exon 8 mutation responsive to imatinib therapy. Veterinary Journal, 2012; 193(1). Disponible en: https://doi.org/10.1016/j.tvjl.2011.10.027

Kobayashi M et al. Imatinib-associated tumour response in a dog with a non-resectable gastrointestinal stromal tumour harbouring a c-kit exon 11 deletion mutation. Veterinary Journal, 2013; 198(1). Disponible en: https://doi.org/10.1016/j.tvjl.2013.05.03

Fonseca-Alves CE et al. Alterations of C-MYC, NKX3.1, and E-cadherin expression in canine prostate carcinogenesis. Microscopy Research and Technique, 2013; 76(12). Disponible en: https://doi.org/10.1002/jemt.22292

de Nardi AB et al. Diagnosis, Prognosis and Treatment of Canine Cutaneous and Subcutaneous Mast Cell Tumors. Cells, 2022; 11(4), 618. Disponible en: https://doi.org/10.3390/cells11040618

Varshney J, Scott MC, Largaespada DA, Subramanian S. Understanding the osteosarcoma pathobiology: A comparative oncology approach. In Veterinary Sciences 2016; (Vol. 3, Issue 1).

Lopez CM, Yu PY, Zhang X, Yilmaz AS, London CA, Fenger JM. MiR-34a regulates the invasive capacity of canine osteosarcoma cell lines. PLoS ONE,2018; 13(1).

Han L, Fu Q, Deng C, Luo L, Xiang T, Zhao H. Immunomodulatory potential of flavonoids for the treatment of autoimmune diseases and tumour. Scandinavian Journal of Immunology, 2022; 95(1). https://doi.org/10.1111/sji.13106

Shiota (Sato) Y et al. Derivation of a new model of lung adenocarcinoma using canine lung cancer organoids for translational research in pulmonary medicine. Biomedicine and Pharmacotherapy, 2023; 165.

Fonseca-Alves CE et al. Alterations of C-MYC, NKX3.1, and E-cadherin expression in canine prostate carcinogenesis. Microscopy Research and Technique,2013; 76(12). https://doi.org/10.1002/jemt.22292

Fletcher S, Prochownik EV.Small-molecule inhibitors of the Myc oncoprotein. In Biochimica et Biophysica Acta - Gene Regulatory Mechanisms2015; (Vol. 1849, Issue 5, pp. 525–543). Elsevier B.V.

Lourenco C. et al. MYC protein interactors in gene transcription and cancer. Nature Reviews Cancer,2021; 21(9), 579–591.

Parker T et al. Rhinoscopic Appearance and Clinical Features of a Nasal Transmissible Venereal Tumor in a Dog. Topics in Companion Animal Medicine, 2021; 42. https://doi.org/10.1016/j.tcam.2020.100476

Das U, Kumar Das A. Review of canine transmissible venereal sarcoma. In Veterinary Research Communications, 2000; Vol. 263(145).

Jung I et al. Relationship of endothelial area with VEGF-A, COX-2, maspin, c-KIT, and DOG-1 immunoreactivity in liposarcomas versus non-lipomatous soft tissue tumors. International Journal of Clinical and Experimental Pathology,2015; 8(2).

Ye Y, Sun WW, Xu RX, Selmic LE, Sun M. Intraoperative assessment of canine soft tissue sarcoma by deep learning enhanced optical coherence tomography. Veterinary and Comparative Oncology, 2021; 19(4), 624–631. https://doi.org/10.1111/vco.12747

Lumsden AL, Young RL, Pezos N, Keating DJ. Huntingtin-associated protein 1: Eutherian adaptation from a TRAK-like protein, conserved gene promoter elements, and localization in the human intestine. BMC Evolutionary Biology, 2016; 16(1).

Elbadawy M et al. Anti-tumor effect of trametinib in bladder cancer organoid and the underlying mechanism. Cancer Biology and Therapy, 2021; 22(5–6).

Abugomaa A et al. Anti-cancer activity of Chaga mushroom (Inonotus obliquus) 2023; 14.

Usher SG, Radford AD, Villiers EJ, Blackwood L. RAS, FLT3, and C-KIT mutations in immunophenotyped canine leukemias. Experimental Hematology, 2009; 37(1).

Usmanova N, Tomilin N, Zhivotovsky B, Kropotov A. Transcription factor GABP/NRF-2 controlling biogenesis of mitochondria regulates basal expression of peroxiredoxin v but the mitochondrial function of peroxiredoxin v is dispensable in the dog. Biochimie, 2011; 93(2). https://doi.org/10.1016/j.biochi.2010.10.002

Katavolos P et al. Preclinical Safety Assessment of a Highly Selective and Potent Dual Small-Molecule Inhibitor of CBP/P300 in Rats and Dogs. Toxicologic Pathology, 2020; 48 (3).

Medley K, Li Z, Lin C, Bearss DJ, Vankayalapati H. Development of BLX-3030, a potent and selective inhibitor of CDK9 for the treatment of NMYC-driven NEPCS. Journal of Clinical Oncology, 2023; 41(16_suppl). https://doi.org/10.1200/jco.2023.41.16_suppl.e17067

Schiffman JD, Breen M. Comparative oncology: what dogs and other species can teach us about humans with cancer. Philosophical Transactions of the Royal Society B: Biological Sciences, 2015; 370(1673), 20140231.

Avery AC.The Genetic and Molecular Basis for Canine Models of Human Leukemia and Lymphoma. In Frontiers in Oncology 2020; 10.

Cowing BE, Saker KE. Polyunsaturated fatty acids and epidermal growth factor receptor/mitogen-activated protein kinase signaling in mammary cancer. In Journal of Nutrition,2001; 131 (4).